Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled Phase 2a clinical trial of OTO-413 in subjects with hearing loss

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled Phase 2a clinical trial of OTO-413 in subjects with hearing loss

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OTO-413 (Primary)
  • Indications Hearing loss
  • Focus Therapeutic Use
  • Sponsors Otonomy [CEASED]

Most Recent Events

  • 13 Oct 2022 Results published in an Otonomy Media Release.
  • 01 Aug 2022 According to an Otonomy media release, enrollment is complete for evaluation of higher dosing with top-line results expected in the fourth quarter of 2022.
  • 09 May 2022 According to an Otonomy media release, enrollment is ongoing for higher dose evaluation and results from the evaluation of higher doses for OTO-413 in hearing loss patients is expected later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top